133 related articles for article (PubMed ID: 16563349)
1. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy.
Needham DJ; Lee JX; Beilharz MW
Biochem Biophys Res Commun; 2006 May; 343(3):684-91. PubMed ID: 16563349
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets.
Pyzik M; Piccirillo CA
J Leukoc Biol; 2007 Aug; 82(2):335-46. PubMed ID: 17475784
[TBL] [Abstract][Full Text] [Related]
3. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
Viehl CT; Moore TT; Liyanage UK; Frey DM; Ehlers JP; Eberlein TJ; Goedegebuure PS; Linehan DC
Ann Surg Oncol; 2006 Sep; 13(9):1252-8. PubMed ID: 16952047
[TBL] [Abstract][Full Text] [Related]
4. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
5. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes.
Tritt M; Sgouroudis E; d'Hennezel E; Albanese A; Piccirillo CA
Diabetes; 2008 Jan; 57(1):113-23. PubMed ID: 17928397
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10.
Maynard CL; Harrington LE; Janowski KM; Oliver JR; Zindl CL; Rudensky AY; Weaver CT
Nat Immunol; 2007 Sep; 8(9):931-41. PubMed ID: 17694059
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4 x Ig converts naive CD4+CD25- T cells into CD4+CD25+ regulatory T cells.
Razmara M; Hilliard B; Ziarani AK; Chen YH; Tykocinski ML
Int Immunol; 2008 Apr; 20(4):471-83. PubMed ID: 18272926
[TBL] [Abstract][Full Text] [Related]
9. CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.
Kuhn A; Beissert S; Krammer PH
Arch Dermatol Res; 2009 Jan; 301(1):71-81. PubMed ID: 18985367
[TBL] [Abstract][Full Text] [Related]
10. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
[TBL] [Abstract][Full Text] [Related]
11. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
[TBL] [Abstract][Full Text] [Related]
12. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.
Larmonier N; Marron M; Zeng Y; Cantrell J; Romanoski A; Sepassi M; Thompson S; Chen X; Andreansky S; Katsanis E
Cancer Immunol Immunother; 2007 Jan; 56(1):48-59. PubMed ID: 16612596
[TBL] [Abstract][Full Text] [Related]
13. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.
Qu Y; Zhang B; Zhao L; Liu G; Ma H; Rao E; Zeng C; Zhao Y
Transpl Immunol; 2007 Apr; 17(3):153-61. PubMed ID: 17331841
[TBL] [Abstract][Full Text] [Related]
14. The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model.
Tadmor T; Zhang Y; Cho HM; Podack ER; Rosenblatt JD
Cancer Immunol Immunother; 2011 May; 60(5):609-19. PubMed ID: 21253724
[TBL] [Abstract][Full Text] [Related]
15. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma.
Meloni F; Morosini M; Solari N; Passadore I; Nascimbene C; Novo M; Ferrari M; Cosentino M; Marino F; Pozzi E; Fietta AM
Hum Immunol; 2006; 67(1-2):1-12. PubMed ID: 16698419
[TBL] [Abstract][Full Text] [Related]
16. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.
Terzieva V; Popova D; Kicheva M; Todorova Y; Markova R; Martinova F; Elenkov I; Yankova M
Int Immunopharmacol; 2009 Jul; 9(7-8):831-6. PubMed ID: 19303058
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
18. Mast cells down-regulate CD4+CD25+ T regulatory cell suppressor function via histamine H1 receptor interaction.
Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
J Immunol; 2009 Sep; 183(5):3014-22. PubMed ID: 19667094
[TBL] [Abstract][Full Text] [Related]
19. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours.
Símová J; Bubeník J; Bieblová J; Rosalia RA; Fric J; Reinis M
Int J Oncol; 2006 Dec; 29(6):1567-71. PubMed ID: 17088998
[TBL] [Abstract][Full Text] [Related]
20. The levels of CD4+CD25+ regulatory T cells in paediatric patients with allergic rhinitis and bronchial asthma.
Lee JH; Yu HH; Wang LC; Yang YH; Lin YT; Chiang BL
Clin Exp Immunol; 2007 Apr; 148(1):53-63. PubMed ID: 17349011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
